Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
Promising results with cancer-fighting virus
May 22, 2008
Jennerex Biotherapeutics, a startup company based on the research of Dr. John Bell at the Ottawa Hospital Research Institute (OHRI) and Dr. David Kirn in San Francisco, has published promising results of a clinical trial with a cancer-fighting virus. The Phase I trial was published online in
Lancet Oncology
on May 19, 2008. Fourteen terminal cancer patients were treated and half survived more than eight months (life expectancy was three to four months).
The trial was conducted in Korea, in partnership with Green Cross Corporation. Further clinical trials will be conducted in Ottawa and other Canadian cities as soon as Health Canada approval is obtained.
Dr. Bell is the Chief Scientific Officer for Jennerex and also a Senior Scientist in the Cancer Therapeutics Program at OHRI (the research arm of The Ottawa Hospital) and a Professor of Medicine at the University of Ottawa.
For more information, see:
CTV Ottawa story
Lancet Oncology
research paper
Jennerex Biotherapeutics
Press release